Liver cirrhosis, stemming from non-alcoholic fatty liver disease (NAFLD), occasionally precedes HCC and involves Bcl-3 (78), while Bcl-3 reduces PGC1α activity, suggesting that higher PGC1α activity might protect against NAFLD-related liver cirrhosis (78, 79). Here, PPARGC1A is linked to metabolic dysfunction-associated steatotic liver disease.